Handelsbanken Fonder AB Purchases Shares of 31,600 Tempus AI, Inc. $TEM

Handelsbanken Fonder AB purchased a new stake in Tempus AI, Inc. (NASDAQ:TEM) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 31,600 shares of the company’s stock, valued at approximately $1,866,000.

Other large investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Tempus AI by 1,459.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock valued at $8,174,000 after acquiring an additional 94,783 shares during the period. Vanguard Group Inc. grew its position in shares of Tempus AI by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after purchasing an additional 1,706,837 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new position in shares of Tempus AI during the 3rd quarter worth approximately $1,695,000. Krane Funds Advisors LLC grew its position in shares of Tempus AI by 218.2% during the 3rd quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock worth $2,427,000 after purchasing an additional 19,358 shares in the last quarter. Finally, Aberdeen Group plc grew its position in shares of Tempus AI by 64.2% during the 4th quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock worth $15,530,000 after purchasing an additional 102,878 shares in the last quarter. 24.22% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. TD Cowen increased their target price on shares of Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Mizuho assumed coverage on shares of Tempus AI in a research report on Thursday, February 19th. They set an “outperform” rating and a $100.00 target price on the stock. Wall Street Zen lowered shares of Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. BTIG Research decreased their target price on shares of Tempus AI from $90.00 to $80.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Tempus AI currently has an average rating of “Moderate Buy” and an average target price of $68.64.

Tempus AI Stock Performance

NASDAQ TEM opened at $46.18 on Tuesday. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The firm has a market capitalization of $8.29 billion, a price-to-earnings ratio of -26.85 and a beta of 3.99. The firm’s 50 day simple moving average is $48.82 and its 200 day simple moving average is $58.82. Tempus AI, Inc. has a 1 year low of $41.73 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.08. The business had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.24) EPS. As a group, research analysts expect that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Ryan M. Bartolucci sold 4,116 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $181,392.12. Following the completion of the transaction, the chief accounting officer owned 74,041 shares of the company’s stock, valued at $3,262,986.87. This represents a 5.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 13,550 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $597,148.50. Following the completion of the transaction, the chief executive officer directly owned 603,558 shares of the company’s stock, valued at approximately $26,598,801.06. The trade was a 2.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 392,057 shares of company stock worth $18,835,714 over the last 90 days. Insiders own 24.26% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.